Cannabinoid receptor 1 promotes hepatocellular carcinoma initiation and progression through multiple mechanisms

Bani Mukhopadhyay, Kornel Schuebel, Partha Mukhopadhyay, Resat Cinar, Grzegorz Godlewski, Keming Xiong, Ken Mackie, Martin Lizak, Qiaoping Yuan, David Goldman, George Kunos

Research output: Contribution to journalArticle

Abstract

Hepatocellular carcinoma (HCC) has high mortality and no adequate treatment. Endocannabinoids interact with hepatic cannabinoid 1 receptors (CB1Rs) to promote hepatocyte proliferation in liver regeneration by inducing cell cycle proteins involved in mitotic progression, including Forkhead Box M1. Because this protein is highly expressed in HCC and contributes to its genesis and progression, we analyzed the involvement of the endocannabinoid/CB1R system in murine and human HCC. Postnatal diethylnitrosamine treatment induced HCC within 8 months in wild-type mice but fewer and smaller tumors in CB1R-/- mice or in wild-type mice treated with the peripheral CB1R antagonist JD5037, as monitored in vivo by serial magnetic resonance imaging. Genome-wide transcriptome analysis revealed CB1R-dependent, tumor-induced up-regulation of the hepatic expression of CB1R, its endogenous ligand anandamide, and a number of tumor-promoting genes, including the GRB2 interactome as well as Forkhead Box M1 and its downstream target, the tryptophan-catalyzing enzyme indoleamine 2,3-dioxygenase. Increased indoleamine 2,3-dioxygenase activity and consequent induction of immunosuppressive T-regulatory cells in tumor tissue promote immune tolerance. Conclusion: The endocannabinoid/CB1R system is up-regulated in chemically induced HCC, resulting in the induction of various tumor-promoting genes, including indoleamine 2,3-dioxygenase; and attenuation of these changes by blockade or genetic ablation of CB1R suppresses the growth of HCC and highlights the therapeutic potential of peripheral CB1R blockade.

Original languageEnglish (US)
Pages (from-to)1615-1626
Number of pages12
JournalHepatology
Volume61
Issue number5
DOIs
StatePublished - May 1 2015
Externally publishedYes

Fingerprint

Cannabinoid Receptors
Hepatocellular Carcinoma
Indoleamine-Pyrrole 2,3,-Dioxygenase
Endocannabinoids
Neoplasms
Cannabinoid Receptor Antagonists
Diethylnitrosamine
Immune Tolerance
Cell Cycle Proteins
Liver Regeneration
Liver
Gene Expression Profiling
Regulatory T-Lymphocytes
Immunosuppressive Agents
Tryptophan
Genes
Hepatocytes
Up-Regulation
Therapeutics
Magnetic Resonance Imaging

ASJC Scopus subject areas

  • Hepatology

Cite this

Mukhopadhyay, B., Schuebel, K., Mukhopadhyay, P., Cinar, R., Godlewski, G., Xiong, K., ... Kunos, G. (2015). Cannabinoid receptor 1 promotes hepatocellular carcinoma initiation and progression through multiple mechanisms. Hepatology, 61(5), 1615-1626. https://doi.org/10.1002/hep.27686

Cannabinoid receptor 1 promotes hepatocellular carcinoma initiation and progression through multiple mechanisms. / Mukhopadhyay, Bani; Schuebel, Kornel; Mukhopadhyay, Partha; Cinar, Resat; Godlewski, Grzegorz; Xiong, Keming; Mackie, Ken; Lizak, Martin; Yuan, Qiaoping; Goldman, David; Kunos, George.

In: Hepatology, Vol. 61, No. 5, 01.05.2015, p. 1615-1626.

Research output: Contribution to journalArticle

Mukhopadhyay, B, Schuebel, K, Mukhopadhyay, P, Cinar, R, Godlewski, G, Xiong, K, Mackie, K, Lizak, M, Yuan, Q, Goldman, D & Kunos, G 2015, 'Cannabinoid receptor 1 promotes hepatocellular carcinoma initiation and progression through multiple mechanisms', Hepatology, vol. 61, no. 5, pp. 1615-1626. https://doi.org/10.1002/hep.27686
Mukhopadhyay, Bani ; Schuebel, Kornel ; Mukhopadhyay, Partha ; Cinar, Resat ; Godlewski, Grzegorz ; Xiong, Keming ; Mackie, Ken ; Lizak, Martin ; Yuan, Qiaoping ; Goldman, David ; Kunos, George. / Cannabinoid receptor 1 promotes hepatocellular carcinoma initiation and progression through multiple mechanisms. In: Hepatology. 2015 ; Vol. 61, No. 5. pp. 1615-1626.
@article{e1919a927e4240a68c8d61d5c74147b8,
title = "Cannabinoid receptor 1 promotes hepatocellular carcinoma initiation and progression through multiple mechanisms",
abstract = "Hepatocellular carcinoma (HCC) has high mortality and no adequate treatment. Endocannabinoids interact with hepatic cannabinoid 1 receptors (CB1Rs) to promote hepatocyte proliferation in liver regeneration by inducing cell cycle proteins involved in mitotic progression, including Forkhead Box M1. Because this protein is highly expressed in HCC and contributes to its genesis and progression, we analyzed the involvement of the endocannabinoid/CB1R system in murine and human HCC. Postnatal diethylnitrosamine treatment induced HCC within 8 months in wild-type mice but fewer and smaller tumors in CB1R-/- mice or in wild-type mice treated with the peripheral CB1R antagonist JD5037, as monitored in vivo by serial magnetic resonance imaging. Genome-wide transcriptome analysis revealed CB1R-dependent, tumor-induced up-regulation of the hepatic expression of CB1R, its endogenous ligand anandamide, and a number of tumor-promoting genes, including the GRB2 interactome as well as Forkhead Box M1 and its downstream target, the tryptophan-catalyzing enzyme indoleamine 2,3-dioxygenase. Increased indoleamine 2,3-dioxygenase activity and consequent induction of immunosuppressive T-regulatory cells in tumor tissue promote immune tolerance. Conclusion: The endocannabinoid/CB1R system is up-regulated in chemically induced HCC, resulting in the induction of various tumor-promoting genes, including indoleamine 2,3-dioxygenase; and attenuation of these changes by blockade or genetic ablation of CB1R suppresses the growth of HCC and highlights the therapeutic potential of peripheral CB1R blockade.",
author = "Bani Mukhopadhyay and Kornel Schuebel and Partha Mukhopadhyay and Resat Cinar and Grzegorz Godlewski and Keming Xiong and Ken Mackie and Martin Lizak and Qiaoping Yuan and David Goldman and George Kunos",
year = "2015",
month = "5",
day = "1",
doi = "10.1002/hep.27686",
language = "English (US)",
volume = "61",
pages = "1615--1626",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Ltd",
number = "5",

}

TY - JOUR

T1 - Cannabinoid receptor 1 promotes hepatocellular carcinoma initiation and progression through multiple mechanisms

AU - Mukhopadhyay, Bani

AU - Schuebel, Kornel

AU - Mukhopadhyay, Partha

AU - Cinar, Resat

AU - Godlewski, Grzegorz

AU - Xiong, Keming

AU - Mackie, Ken

AU - Lizak, Martin

AU - Yuan, Qiaoping

AU - Goldman, David

AU - Kunos, George

PY - 2015/5/1

Y1 - 2015/5/1

N2 - Hepatocellular carcinoma (HCC) has high mortality and no adequate treatment. Endocannabinoids interact with hepatic cannabinoid 1 receptors (CB1Rs) to promote hepatocyte proliferation in liver regeneration by inducing cell cycle proteins involved in mitotic progression, including Forkhead Box M1. Because this protein is highly expressed in HCC and contributes to its genesis and progression, we analyzed the involvement of the endocannabinoid/CB1R system in murine and human HCC. Postnatal diethylnitrosamine treatment induced HCC within 8 months in wild-type mice but fewer and smaller tumors in CB1R-/- mice or in wild-type mice treated with the peripheral CB1R antagonist JD5037, as monitored in vivo by serial magnetic resonance imaging. Genome-wide transcriptome analysis revealed CB1R-dependent, tumor-induced up-regulation of the hepatic expression of CB1R, its endogenous ligand anandamide, and a number of tumor-promoting genes, including the GRB2 interactome as well as Forkhead Box M1 and its downstream target, the tryptophan-catalyzing enzyme indoleamine 2,3-dioxygenase. Increased indoleamine 2,3-dioxygenase activity and consequent induction of immunosuppressive T-regulatory cells in tumor tissue promote immune tolerance. Conclusion: The endocannabinoid/CB1R system is up-regulated in chemically induced HCC, resulting in the induction of various tumor-promoting genes, including indoleamine 2,3-dioxygenase; and attenuation of these changes by blockade or genetic ablation of CB1R suppresses the growth of HCC and highlights the therapeutic potential of peripheral CB1R blockade.

AB - Hepatocellular carcinoma (HCC) has high mortality and no adequate treatment. Endocannabinoids interact with hepatic cannabinoid 1 receptors (CB1Rs) to promote hepatocyte proliferation in liver regeneration by inducing cell cycle proteins involved in mitotic progression, including Forkhead Box M1. Because this protein is highly expressed in HCC and contributes to its genesis and progression, we analyzed the involvement of the endocannabinoid/CB1R system in murine and human HCC. Postnatal diethylnitrosamine treatment induced HCC within 8 months in wild-type mice but fewer and smaller tumors in CB1R-/- mice or in wild-type mice treated with the peripheral CB1R antagonist JD5037, as monitored in vivo by serial magnetic resonance imaging. Genome-wide transcriptome analysis revealed CB1R-dependent, tumor-induced up-regulation of the hepatic expression of CB1R, its endogenous ligand anandamide, and a number of tumor-promoting genes, including the GRB2 interactome as well as Forkhead Box M1 and its downstream target, the tryptophan-catalyzing enzyme indoleamine 2,3-dioxygenase. Increased indoleamine 2,3-dioxygenase activity and consequent induction of immunosuppressive T-regulatory cells in tumor tissue promote immune tolerance. Conclusion: The endocannabinoid/CB1R system is up-regulated in chemically induced HCC, resulting in the induction of various tumor-promoting genes, including indoleamine 2,3-dioxygenase; and attenuation of these changes by blockade or genetic ablation of CB1R suppresses the growth of HCC and highlights the therapeutic potential of peripheral CB1R blockade.

UR - http://www.scopus.com/inward/record.url?scp=84928204268&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928204268&partnerID=8YFLogxK

U2 - 10.1002/hep.27686

DO - 10.1002/hep.27686

M3 - Article

C2 - 25580584

AN - SCOPUS:84928204268

VL - 61

SP - 1615

EP - 1626

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 5

ER -